Indaptus Therapeutics, Inc.
INDP
$2.55
$0.4722.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.56M | 10.40M | 10.49M | 6.87M | 7.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.77M | 17.42M | 19.83M | 15.85M | 16.34M |
| Operating Income | -14.77M | -17.42M | -19.83M | -15.85M | -16.34M |
| Income Before Tax | -15.42M | -18.86M | -20.85M | -16.87M | -16.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.42 | -18.86 | -20.85 | -16.87 | -16.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.42M | -18.86M | -20.85M | -16.87M | -16.96M |
| EBIT | -14.77M | -17.42M | -19.83M | -15.85M | -16.34M |
| EBITDA | -10.80M | -15.26M | -19.83M | -15.85M | -16.34M |
| EPS Basic | -7.75 | -16.83 | -25.70 | -31.77 | -37.82 |
| Normalized Basic EPS | -4.84 | -10.52 | -16.06 | -19.86 | -23.64 |
| EPS Diluted | -7.75 | -16.83 | -25.70 | -31.77 | -37.82 |
| Normalized Diluted EPS | -4.84 | -10.52 | -16.06 | -19.86 | -23.64 |
| Average Basic Shares Outstanding | 129.88M | 14.33M | 3.87M | 2.46M | 1.80M |
| Average Diluted Shares Outstanding | 129.88M | 14.33M | 3.87M | 2.46M | 1.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |